Literature DB >> 27814503

Epidemiology of DSM-5 bipolar I disorder: Results from the National Epidemiologic Survey on Alcohol and Related Conditions - III.

Carlos Blanco1, Wilson M Compton2, Tulshi D Saha3, Benjamin I Goldstein4, W June Ruan5, Boji Huang6, Bridget F Grant7.   

Abstract

BACKGROUND: The objective of this study was to present 12-month and lifetime prevalence, correlates, comorbidity, treatment and disability of DSM-5 bipolar I disorder.
METHODS: Nationally representative U.S. adult sample (N = 36,309), the 2012-2013 National Epidemiologic Survey on Alcohol and Related Conditions - III.
RESULTS: Prevalences of 12-month and lifetime DSM-5 bipolar I disorder were 1.5% and 2.1% and did not differ between men (1.6% and 2.2%) and women (1.5% and 2.0%). Prevalences of bipolar I disorder were greater among Native Americans, and lower among Blacks, Hispanics and Asians/Pacific Islanders than whites. Rates were also lower among younger than older individuals, those previously married than currently married and with lower education and income relative to higher education and income. Bipolar I disorder was more strongly related to borderline and schizotypal personality disorders (adjusted odds ratios (AORS) = 2.2-4.7)), than to anxiety disorders (AORs = 1.3-2.9), and substance use disorders (AORs = 1.3-2.1) overall and among men and women. Quality of life was lower among individuals with bipolar I disorder relative to those without the disorder. Treatment rates among individuals with bipolar I disorder were low in the total sample (46%, SE = 2.63), among men (36.7%, SE = 3.82) and among women (55.8%, SE = 3.32).
CONCLUSIONS: Bipolar I disorder continues to be common disabling and highly comorbid disorder among men and women, contributing substantially to low quality of life and burden of disease in our society. Copyright Â
© 2016. Published by Elsevier Ltd.

Entities:  

Keywords:  Bipolar I disorder; Comorbidity; Epidemiology; Prevalence; Treatment

Mesh:

Year:  2016        PMID: 27814503      PMCID: PMC7416534          DOI: 10.1016/j.jpsychires.2016.10.003

Source DB:  PubMed          Journal:  J Psychiatr Res        ISSN: 0022-3956            Impact factor:   4.791


  69 in total

Review 1.  The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid personality disorders.

Authors:  Michael Rosenbluth; Glenda Macqueen; Roger S McIntyre; Serge Beaulieu; Ayal Schaffer
Journal:  Ann Clin Psychiatry       Date:  2012-02       Impact factor: 1.567

Review 2.  The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid substance use disorders.

Authors:  Serge Beaulieu; Sybille Saury; Jitender Sareen; Jacques Tremblay; Christian G Schütz; Roger S McIntyre; Ayal Schaffer
Journal:  Ann Clin Psychiatry       Date:  2012-02       Impact factor: 1.567

3.  Tests of data quality, scaling assumptions, and reliability of the SF-36 in eleven countries: results from the IQOLA Project. International Quality of Life Assessment.

Authors:  B Gandek; J E Ware; N K Aaronson; J Alonso; G Apolone; J Bjorner; J Brazier; M Bullinger; S Fukuhara; S Kaasa; A Leplège; M Sullivan
Journal:  J Clin Epidemiol       Date:  1998-11       Impact factor: 6.437

4.  Twelve-month prevalence of psychiatric disorders and treatment-seeking among Asian Americans/Pacific Islanders in the United States: results from the National Epidemiological Survey on Alcohol and Related Conditions.

Authors:  Yang Xu; Mayumi Okuda; Yih-Ing Hser; Deborah Hasin; Shang-Min Liu; Bridget F Grant; Carlos Blanco
Journal:  J Psychiatr Res       Date:  2011-01-15       Impact factor: 4.791

5.  Mental disorders and risk of suicide attempt: a national prospective study.

Authors:  N Hoertel; S Franco; M M Wall; M A Oquendo; B T Kerridge; F Limosin; C Blanco
Journal:  Mol Psychiatry       Date:  2015-05-18       Impact factor: 15.992

6.  Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication.

Authors:  Kathleen R Merikangas; Hagop S Akiskal; Jules Angst; Paul E Greenberg; Robert M A Hirschfeld; Maria Petukhova; Ronald C Kessler
Journal:  Arch Gen Psychiatry       Date:  2007-05

7.  Comorbidities and mortality in bipolar disorder: a Swedish national cohort study.

Authors:  Casey Crump; Kristina Sundquist; Marilyn A Winkleby; Jan Sundquist
Journal:  JAMA Psychiatry       Date:  2013-09       Impact factor: 21.596

8.  Acculturation and drug use disorders among Hispanics in the U.S.

Authors:  Carlos Blanco; Carmen Morcillo; Margarita Alegría; María Cecilia Dedios; Pablo Fernández-Navarro; Rosa Regincos; Shuai Wang
Journal:  J Psychiatr Res       Date:  2012-11-03       Impact factor: 4.791

Review 9.  The prevalence of bipolar disorder in general primary care samples: a systematic review.

Authors:  Joseph M Cerimele; Lydia A Chwastiak; Sherry Dodson; Wayne J Katon
Journal:  Gen Hosp Psychiatry       Date:  2013-10-18       Impact factor: 3.238

10.  Childhood maltreatment and the course of bipolar disorders among adults: epidemiologic evidence of dose-response effects.

Authors:  Regina Sala; Benjamin I Goldstein; Shuai Wang; Carlos Blanco
Journal:  J Affect Disord       Date:  2014-04-23       Impact factor: 4.839

View more
  24 in total

1.  Pharmacological Treatment of Bipolar Disorder with Comorbid Alcohol Use Disorder.

Authors:  Andrew Naglich; Bryon Adinoff; E Sherwood Brown
Journal:  CNS Drugs       Date:  2017-08       Impact factor: 5.749

2.  Ethical Issues in the Diagnosis and Treatment of Bipolar Disorders.

Authors:  Michael J Ostacher
Journal:  Focus (Am Psychiatr Publ)       Date:  2019-07-16

3.  Epidemiology of Adult DSM-5 Major Depressive Disorder and Its Specifiers in the United States.

Authors:  Deborah S Hasin; Aaron L Sarvet; Jacquelyn L Meyers; Tulshi D Saha; W June Ruan; Malka Stohl; Bridget F Grant
Journal:  JAMA Psychiatry       Date:  2018-04-01       Impact factor: 21.596

Review 4.  Psychopharmacology and Experimental Therapeutics for Bipolar Depression.

Authors:  Manish K Jha; James W Murrough
Journal:  Focus (Am Psychiatr Publ)       Date:  2019-07-16

Review 5.  Epidemiology and risk factors for bipolar disorder.

Authors:  Tobias A Rowland; Steven Marwaha
Journal:  Ther Adv Psychopharmacol       Date:  2018-04-26

6.  Associations among Substance Use, Mental Health Disorders, and Self-Harm in a Prison Population: Examining Group Risk for Suicide Attempt.

Authors:  Madison L Gates; Asher Turney; Elizabeth Ferguson; Veronica Walker; Michelle Staples-Horne
Journal:  Int J Environ Res Public Health       Date:  2017-03-20       Impact factor: 3.390

Review 7.  Molecular Mechanisms of Bipolar Disorder: Progress Made and Future Challenges.

Authors:  Yeni Kim; Renata Santos; Fred H Gage; Maria C Marchetto
Journal:  Front Cell Neurosci       Date:  2017-02-14       Impact factor: 5.505

8.  Polygenic risk scores for schizophrenia and bipolar disorder associate with addiction.

Authors:  Gunnar W Reginsson; Andres Ingason; Jack Euesden; Gyda Bjornsdottir; Sigurgeir Olafsson; Engilbert Sigurdsson; Hogni Oskarsson; Thorarinn Tyrfingsson; Valgerdur Runarsdottir; Ingunn Hansdottir; Stacy Steinberg; Hreinn Stefansson; Daniel F Gudbjartsson; Thorgeir E Thorgeirsson; Kari Stefansson
Journal:  Addict Biol       Date:  2017-02-23       Impact factor: 4.280

9.  The importance and implications of comparator selection in pharmacoepidemiologic research.

Authors:  Monica D'Arcy; Til Stürmer; Jennifer L Lund
Journal:  Curr Epidemiol Rep       Date:  2018-07-06

Review 10.  Systematic literature review on patterns of pharmacological treatment and adherence among patients with bipolar disorder type I in the USA.

Authors:  Mallik Greene; Luciano Paladini; Teresa Lemmer; Alexandra Piedade; Maelys Touya; Otavio Clark
Journal:  Neuropsychiatr Dis Treat       Date:  2018-06-14       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.